Elranatamab solution for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Elrexfio
Company
Pfizer Europe MA EEIG (EU authorization holder)
Medicine type
Biologic
Therapeutic area
Oncology
Indications recorded in the public source
EU: Adults with relapsed and refractory multiple myeloma after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, with progression since the last treatment.
Indication source and scope
English EMA EPAR overview and product details accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions